CLINICAL TRIALS PROFILE FOR TIOTROPIUM BROMIDE
✉ Email this page to a colleague
All Clinical Trials for tiotropium bromide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00139932 ↗ | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | Completed | Integrated Therapeutics Group | Phase 4 | 2005-09-01 | This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD. |
| NCT00139932 ↗ | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | Completed | Novartis | Phase 4 | 2005-09-01 | This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD. |
| NCT00139932 ↗ | Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2005-09-01 | This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD. |
| NCT00144326 ↗ | A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (C | Completed | Boehringer Ingelheim | Phase 3 | 2003-07-01 | The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of daily physical activity observed in COPD patients, measured using an accelerometer. |
| NCT00157235 ↗ | Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients | Completed | Boehringer Ingelheim | Phase 3 | 2002-09-01 | The objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation. |
| NCT00239408 ↗ | Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). | Completed | Boehringer Ingelheim | Phase 4 | 2002-12-01 | Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status. |
| NCT00239434 ↗ | A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 3 | 2003-06-01 | The objective of this study is to compare the bronchodilator efficacy and safety of once daily dosing of tiotropium inhalation capsules (18 ?g) and Atrovent? MDI (2 puffs of ipratropium bromide 20 ?g four times daily) in patients with chronic obstructive pulmonary disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tiotropium bromide
Condition Name
Clinical Trial Locations for tiotropium bromide
Trials by Country
Clinical Trial Progress for tiotropium bromide
Clinical Trial Phase
Clinical Trial Sponsors for tiotropium bromide
Sponsor Name
